In this study, we report the pharmacokinetics and in vivo fate of intra-articularly transplanted human mesenchymal stem cells (MSCs) in comparison with those of intravenously administered cells. Bone marrow-derived human clonal mesenchymal stem cells (hcMSCs) were transplanted to nude mice through intravenous or intra-articular routes. The numbers of hcMSCs in blood and tissue samples were measured by the quantitative real-time–polymerase chain reaction (qPCR) with human Alu (hAlu) as a detection marker. Following intra-articular transplantation, the blood levels of hcMSCs peaked 8 h postdose and gradually diminished, showing a 95-fold higher mean residence time than hcMSCs delivered through the intravenous route. Unlike intravenously administered hcMSCs, intra-articularly injected hcMSCs were mainly retained at injection joint sites where their levels 8 h postdose were 116-fold higher than those in muscle tissues. Regardless of injection routes, biodistribution patterns did not significantly differ between normal and osteoarthritis-induced mice. Quantitative analysis using hAlu-specific qPCR revealed that hcMSC levels in joint tissues were significantly higher than those in muscle tissues 120 days postdose. These dramatic differences in kinetic behavior and fate of intra-articularly transplanted hcMSCs compared with intravenously administered hcMSCs may provide insights useful for the development of human MSCs for arthritis therapeutics.
Get full access to this article
View all access options for this article.
References
1.
RaJC, ShinIS, KimSH, KangSK, KangBC, LeeHY, KimYJ, JoJY, YoonEJ, ChoiHJ and KwonE. (2011). Safety of intravenous infusion of human adipose tissue-derived MSC in animals and humans. Stem Cells Dev, 20:1297–1308.
2.
GuE, ChenWY, GuJ, BurridgeP and WuJC. (2012). Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics, 2:335–345.
3.
De MiguelMP, Fuentes-JuliánS, Blázquez-MartínezA, PascualCY, AllerMA, AriasJ and Arnalich-MontielF. (2012). Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med, 12:574–591.
4.
NajiA, Rouas-FreissN, DurrbachA, CarosellaED, SensébéL and DeschaseauxF. (2013). Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells, 31:2296–2303.
5.
MacFarlaneRJ, GrahamSM, DaviesPS, KorresN, TsouchnicaH, HeliotisM, MantalarisA and TsiridisE. (2013). Anti-inflammatory role and immunomodulation of mesenchymal stem cells in systemic joint diseases: potential for treatment. Expert Opin Ther Targets, 17:243–254.
6.
SarugaserR, HanounL, KeatingA, StanfordWL and DaviesJE. (2009). Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PLoS One, 4:e6498
7.
WilliamsAR and HareJM. (2011). Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res, 109:923–940.
8.
LoWC, ChenWH, LinTC, HwangSM, ZengR, HsuWC, ChiangYM, LiuMC, WilliamsDF and DengWP. (2013). Preferential therapy for osteoarthritis by cord blood MSC through regulation of chondrogenic cytokines. Biomaterials, 3:4739–4748.
9.
ZhouB, YuanJ, ZhouY, GhawjiMJr., DengYP, LeeAJ, NairU, KangAH, BrandDD and YooTJ. (2011). Administering human adipose-derived mesenchymal stem cells to prevent and treat experimental arthritis. Clin Immunol, 141:328–337.
10.
PapadopoulouA, YiangouM, AthanasiouE, ZogasN, KaloyannidisP, BatsisI, FassasA, AnagnostopoulosA and YannakiE. (2012). Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann Rheum Dis, 71:1733–1740.
11.
SwartJF, de RoockS, HofhuisFM, RozemullerH, van den BroekT, MoererP, BroereF, van WijkF, KuisW, et al. (2014). Mesenchymal stem cell therapy in proteoglycan induced arthritis. Ann Rheum Dis [Epub ahead of print]; DOI: 10.1136/annrheumdis-2013-204147.
12.
JiangL, MaA, SongL, HuY, DunH, DalozeP, YuY, JiangJ, ZafarullahM and ChenH. (2014). Cartilage regeneration by selected chondrogenic clonal mesenchymal stem cells in the collagenase-induced monkey osteoarthritis model. J Tissue Eng Regen Med, 8:896–905.
13.
NamH, KarunanithiP, LooWC, NaveenS, ChenH, HussinP, ChanL and KamarulT. (2013). The effects of staged intra-articular injection of cultured autologous mesenchymal stromal cells on the repair of damaged cartilage: a pilot study in caprine model. Arthritis Res Ther, 15:R129
14.
OrozcoL, MunarA, SolerR, AlbercaM, SolerF, HuguetM, SentísJ, SánchezA and García-SanchoJ. (2013). Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation, 95:1535–1541.
15.
WoodJA, ChungDJ, ParkSA, ZwingenbergerAL, ReillyCM, LyI, WalkerNJ, VernauW, HayashiK, et al. (2012). Periocular and intra-articular injection of canine adipose-derived MSC: an in vivo imaging and migration study. J Ocul Pharmacol Ther, 28:307–317.
16.
DesandoG, CavalloC, SartoniF, MartiniL, ParrilliA, VeronesiF, FiniM, GiardinoR, FacchiniA and GrigoloB. (2013). Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model. Arthritis Res Ther, 15:R22
17.
SongSU, KimCS, YoonSP, KimSK, LeeMH, KangJS, ChoiGS, MoonSH, ChoiMS, ChoYK and SonBK. (2008). Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion. Stem Cells Dev, 17:451–461.
18.
YooHS, YiT, ChoYK, KimWC, SongSU and JeonMS. (2013). Mesenchymal stem cell lines isolated by different isolation methods show variations in the regulation of graft-versus-host disease. Immune Netw, 13:133–140.
19.
YiT, KimWK, ChoiJS, SongSY, HanJ, KimJH, KimWS, ParkSG, LeeHJ, et al. (2014). Isolation of adipose-derived stem cells by using a subfractionation culturing method. Expert Opin Biol Ther, 29:1–10.
20.
BowlesRD, MataBA, BellRD, MwangiTK, HuebnerJL, KrausVB and SettonLA. (2014). In vivo luminescence imaging of NF-kB activity and serum cytokine levels predict pain sensitivities in a rodent model of osteoarthritis. Arthritis Rheum, 66:637–646.
21.
BiancoP, CaoX, FrenettePS, MaoJJ, RobeyPG, SimmonsPJ and WangC-Y. (2013). he meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med, 19:35–42.
22.
AndersonP, Carrillo-GálvezAB, García-PérezA, CoboM and MartínF. (2013). CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities. PLoS One, 8:e76979
23.
JungKH, SongSU, YiT, JeonMS, HongSW, ZhengHM, LeeHS, ChoiMJ, LeeDH and HongSS. (2011). Human bone marrow-derived clonal MSC inhibit inflammation and reduce acute pancreatitis in rats. Gastroenterology, 140:998–1008.
24.
YiT, LeeDS, JeonMS, KwonSW and SongSU. (2012). Gene expression profile reveals that STAT2 is involved in the immunosuppressive function of human bone marrow-derived MSC. Gene, 497:131–139.
25.
KimYM, YiT, ChoiJS, LeeS, JangYH, KimCH, SongSU and LimJY. (2013). Bone marrow-derived clonal MSC as a source of cell therapy for promoting vocal fold wound healing. Ann Otol Rhinol Laryngol, 122:121–130.
26.
AdeC, Roy-EngelAM and DeiningerPL. (2013). Alu elements: an intrinsic source of human genome instability. Curr Opin Virol, 3:639–645.
27.
ChengK, BentenD, BhargavaK, InadaM, JosephB, PalestroC and GuptaS. (2009). Hepatic targeting and biodistribution of human fetal liver stem/progenitor cells and adult hepatocytes in mice. Hepatology, 50:1194–1203.
28.
DetanteO, MoisanA, DimastromatteoJ, RichardMJ, RiouL, GrillonE, BarbierE, DesruetMD, De FraipontF, et al. (2009). Intravenous administration of 99mTc-HMPAO-labeled human MSC after stroke: in vivo imaging and biodistribution. Cell Transplant, 18:1369–1379.
WuT, LangJ, SunX, ZhangB, LiuY and AnR. (2013). Monitoring bone marrow stem cells with a reporter gene system in experimental middle cerebral artery occlusion rat models. J Nucl Med, 54:984–989.
31.
ThaciB, AhmedAU, UlasovIV, TobiasAL, HanY, AboodyKS and LesniakMS. (2012). Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther, 19:431–442.
32.
StenderS, MurphyM, O'BrienT, StengaardC, Ulrich-VintherM and SøballeK. (2007). Adeno-associated viral vector transduction of human mesenchymal stem cells. Eur Cell Mater, 13:93–99.
33.
SchrepferS, DeuseT, ReichenspurnerH, FischbeinMP, RobbinsRC and PelletierMP. (2007). Stem cell transplantation: the lung barrier. Transplant Proc, 39:573–576.
34.
FischerUM, HartingMT, JimenezF, Monzon-PosadasWO, XueH, SavitzSI, LaineGA and CoxCS. (2009). Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev, 18:683–692.
35.
ToupetK, MaumusM, PeyrafitteJA, BourinP, van LentPL, FerreiraR, OrsettiB, PirotN, CasteillaL, JorgensenC and NoelD. (2013). Long-term detection of human adipose-derived MSC after intraarticular injection in SCID mice. Arthritis Rheum, 65:1786–1794.
36.
KurthTB, Dell'accioF, CrouchV, AugelloA, SharpePT and De BariC. (2011). Functional mesenchymal stem cell niches in adult mouse knee joint synovium in vivo. Arthritis Rheum, 63:1289–1300.
37.
FisherMC, FerrariD, LiY, ShepardJB, PattersonSE, AndersonN and DealyCN. (2012). The potential of human embryonic stem cells for articular cartilage repair and osteoarthritis treatment. Rheumatol Curr Res, S3:004
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
